We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
51
Assembly Biosciences
ASMB
$495M
$8.73M 0.07%
20,833
– –
AGIO icon
52
Agios Pharmaceuticals
AGIO
$2.09B
$8.59M 0.07%
128,666
– –
SYRS
53
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.46M 0.07%
57,484
– –
ACHN
54
DELISTED
Achillion Pharmaceuticals
ACHN
$8.34M 0.07%
1,856,637
– –
CFRX
55
DELISTED
ContraFect Corporation
CFRX
$7.94M 0.06%
8,941
+3,884
+77% +$3.67M
CBIO
56
Crescent Biopharma
CBIO
$580M
$7.88M 0.06%
5,633
– –
NBRV
57
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.68M 0.06%
3,753
+2,353
+168% +$5.52M
ALKS icon
58
Alkermes
ALKS
$8.13B
$7.64M 0.06%
150,251
– –
GWPH
59
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.61M 0.06%
+75,000
New +$8.03M
VNDA icon
60
Vanda Pharmaceuticals
VNDA
$302M
$7.59M 0.06%
+423,884
New +$7.09M
DMTX
61
DELISTED
Dimension Therapeutics, Inc
DMTX
$7.51M 0.06%
1,251,881
– –
STML
62
DELISTED
Stemline Therapeutics, Inc.
STML
$7.03M 0.06%
633,497
– –
MGNX icon
63
MacroGenics
MGNX
$234M
$6.72M 0.05%
363,676
– –
RIGL icon
64
Rigel Pharmaceuticals
RIGL
$716M
$6.4M 0.05%
251,888
– –
TTPH
65
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6.39M 0.05%
+46,750
New +$6.25M
FSTX
66
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$6.28M 0.05%
93,286
– –
XLRN
67
DELISTED
Acceleron Pharma
XLRN
$6.12M 0.05%
163,900
+135,135
+470% +$4.69M
GNMX
68
DELISTED
Aevi Genomic Medicine Inc
GNMX
$5.73M 0.05%
4,546,426
+2,928,337
+181% +$3.74M
SYRE icon
69
Spyre Therapeutics
SYRE
$8.32B
$5.61M 0.05%
45,515
– –
LJPC
70
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5.38M 0.04%
154,675
-350,057
-69% -$11.3M
RNAC icon
71
Cartesian Therapeutics
RNAC
$221M
$5.29M 0.04%
9,660
– –
VYGR icon
72
Voyager Therapeutics
VYGR
$185M
$4.88M 0.04%
+237,014
New +$2.67M
EPZM
73
DELISTED
Epizyme, Inc
EPZM
$4.43M 0.04%
232,481
– –
CMTA
74
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$4.22M 0.03%
+250,000
New +$4.09M
ALBO
75
DELISTED
Albireo Pharma Inc
ALBO
$4.19M 0.03%
200,000
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Baker Bros. Advisors held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Baker Bros. Advisors added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Baker Bros. Advisors's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Baker Bros. Advisors fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Baker Bros. Advisors opened 9 new positions and closed 9 in Q3 2017.
  • Baker Bros. Advisors's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.